[15] UK-licensed cannabis-based products include: Epidyolex (cannabidiol): for severe, treatment-resistant epilepsy (Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex) Sativex (nabiximols): for muscle spasticity in multiple sclerosis where other treatments have failed [15] Nabilone (Cesamet): for chemotherapy-induced nausea and vomiting unresponsive to standard antiemetics Even for these licensed indications, NICE guidance emphasises that cannabis-based products should only be considered after conventional treatments have been tried, and prescribing decisions must be made by specialists with appropriate expertise
The follow-up duration for each cohort is detailed in Supplementary Table 2
(PubMed) Council on Environmental Health, Rogan WJ, Paulson JA, et al
How the program works From your first visit, everything is provider-led and built around your health history: A consultation and full medical history to confirm semaglutide is appropriate for you Baseline lab work and vitals, with ongoing monitoring FDA-approved medication prescribed when clinically appropriate Gradual, supervised dose titration to manage side effects Regular provider check-ins plus nutrition and lifestyle support Who it's for Semaglutide programs are generally for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure or type 2 diabetes, who have struggled to lose weight with diet and exercise alone
